The future of 'bioprocessing' for medical therapies

What's in store for the future of industrial bioprocessing for medical therapies, which involves the use of living organisms or cells to create drugs or other agents? Will the batch or continuous bioprocessing platform dominate biomanufacturing of human therapeutics down the road? Three pioneers in the field address these questions in an upcoming issue of Biotechnology and Bioengineering.

With batch bioprocessing, components are transferred as a batch from one holding vessel or processing equipment to the next, while with continuous bioprocessing, there is a continuous flow like an assembly line. Dr. Matthew Croughan notes that we will never require a biopharmaceutical plant that truly needs to be continuous on a capacity basis. "We will never need to process 50,000 barrels—8 M liters—or more per day, like a continuous oil refinery," he said.

Dr. Konstantin Konstantinov and Dr. Charles Cooney stress that while we shouldn't close existing batch operations, methods are likely to evolve around continuous . Therefore, the development of this new platform should be given serious consideration.

Explore further

Henry Ford's ideas may cut the cost and speed production of medicines

More information: Croughan, M. S., Konstantinov, K. B. and Cooney, C. (2015), The future of industrial bioprocessing: Batch or continuous?. Biotechnol. Bioeng., 112: 648-651. DOI: 10.1002/bit.25529
Journal information: Biotechnology and Bioengineering

Provided by Wiley
Citation: The future of 'bioprocessing' for medical therapies (2015, March 17) retrieved 25 May 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more